EGFR targeting of solid tumors

Caio M. Rocha-Lima, Heloisa P. Soares, Luis E. Raez, Rakesh Singal

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Background: Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many patients with cancer. Methods: We review the current status of several EGFR-targeted therapies in cancer patients and address the efficacy of theses drugs as monotherapy or in combination with other drugs and/or treatments. Results: Cetuximab is the most widely studied anti-EGFR monoclonal antibody. Other monoclonal antibody agents under investigation are panitumumab, matuzumab, MDX-447, nimutozumab, and mAb806. Extensive research has also evaluated the efficacy of EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib, EKB-569, lapatinib (GW572016), PKI-166, and canertinib (CI-1033). All of these agents have been studied for the treatment of colorectal, lung, breast, pancreatic, renal, head and neck, gynecologic, and prostate cancer. Currently, cetuximab and panitumumab are FDA approved for the treatment of metastatic colorectal cancer. Additionally, cetuximab is approved for head and neck cancer. Erlotinib is FDA approved for advanced/metastatic lung cancer. Erlotinib in combination with gemcitabine is approved for advanced/metastatic pancreatic cancer treatment. Conclusions: EGFR-targeted agents have already shown utility in different scenarios. Researchers are continuously investigating additional cancer types and combined treatment modalities that could also benefit from the use of EGFR-targeted agents. Careful patient selection through the identification of specific biologic markers, such as gene expression, genomic polymorphism, and posttranslational modifications of EGFR downstream effectors, most likely will contribute to the successful use of these agents.

Original languageEnglish
Pages (from-to)295-304
Number of pages10
JournalCancer Control
Volume14
Issue number3
StatePublished - Jul 1 2007

Fingerprint

Epidermal Growth Factor Receptor
Neoplasms
Head and Neck Neoplasms
gemcitabine
Therapeutics
Monoclonal Antibodies
Post Translational Protein Processing
Pancreatic Neoplasms
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Patient Selection
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Breast
Biomarkers
Research Personnel
Clinical Trials
Kidney
Gene Expression

ASJC Scopus subject areas

  • Oncology

Cite this

Rocha-Lima, C. M., Soares, H. P., Raez, L. E., & Singal, R. (2007). EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304.

EGFR targeting of solid tumors. / Rocha-Lima, Caio M.; Soares, Heloisa P.; Raez, Luis E.; Singal, Rakesh.

In: Cancer Control, Vol. 14, No. 3, 01.07.2007, p. 295-304.

Research output: Contribution to journalArticle

Rocha-Lima, CM, Soares, HP, Raez, LE & Singal, R 2007, 'EGFR targeting of solid tumors', Cancer Control, vol. 14, no. 3, pp. 295-304.
Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007 Jul 1;14(3):295-304.
Rocha-Lima, Caio M. ; Soares, Heloisa P. ; Raez, Luis E. ; Singal, Rakesh. / EGFR targeting of solid tumors. In: Cancer Control. 2007 ; Vol. 14, No. 3. pp. 295-304.
@article{a10e366675c54683902e1b91557df509,
title = "EGFR targeting of solid tumors",
abstract = "Background: Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many patients with cancer. Methods: We review the current status of several EGFR-targeted therapies in cancer patients and address the efficacy of theses drugs as monotherapy or in combination with other drugs and/or treatments. Results: Cetuximab is the most widely studied anti-EGFR monoclonal antibody. Other monoclonal antibody agents under investigation are panitumumab, matuzumab, MDX-447, nimutozumab, and mAb806. Extensive research has also evaluated the efficacy of EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib, EKB-569, lapatinib (GW572016), PKI-166, and canertinib (CI-1033). All of these agents have been studied for the treatment of colorectal, lung, breast, pancreatic, renal, head and neck, gynecologic, and prostate cancer. Currently, cetuximab and panitumumab are FDA approved for the treatment of metastatic colorectal cancer. Additionally, cetuximab is approved for head and neck cancer. Erlotinib is FDA approved for advanced/metastatic lung cancer. Erlotinib in combination with gemcitabine is approved for advanced/metastatic pancreatic cancer treatment. Conclusions: EGFR-targeted agents have already shown utility in different scenarios. Researchers are continuously investigating additional cancer types and combined treatment modalities that could also benefit from the use of EGFR-targeted agents. Careful patient selection through the identification of specific biologic markers, such as gene expression, genomic polymorphism, and posttranslational modifications of EGFR downstream effectors, most likely will contribute to the successful use of these agents.",
author = "Rocha-Lima, {Caio M.} and Soares, {Heloisa P.} and Raez, {Luis E.} and Rakesh Singal",
year = "2007",
month = "7",
day = "1",
language = "English",
volume = "14",
pages = "295--304",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "3",

}

TY - JOUR

T1 - EGFR targeting of solid tumors

AU - Rocha-Lima, Caio M.

AU - Soares, Heloisa P.

AU - Raez, Luis E.

AU - Singal, Rakesh

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background: Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many patients with cancer. Methods: We review the current status of several EGFR-targeted therapies in cancer patients and address the efficacy of theses drugs as monotherapy or in combination with other drugs and/or treatments. Results: Cetuximab is the most widely studied anti-EGFR monoclonal antibody. Other monoclonal antibody agents under investigation are panitumumab, matuzumab, MDX-447, nimutozumab, and mAb806. Extensive research has also evaluated the efficacy of EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib, EKB-569, lapatinib (GW572016), PKI-166, and canertinib (CI-1033). All of these agents have been studied for the treatment of colorectal, lung, breast, pancreatic, renal, head and neck, gynecologic, and prostate cancer. Currently, cetuximab and panitumumab are FDA approved for the treatment of metastatic colorectal cancer. Additionally, cetuximab is approved for head and neck cancer. Erlotinib is FDA approved for advanced/metastatic lung cancer. Erlotinib in combination with gemcitabine is approved for advanced/metastatic pancreatic cancer treatment. Conclusions: EGFR-targeted agents have already shown utility in different scenarios. Researchers are continuously investigating additional cancer types and combined treatment modalities that could also benefit from the use of EGFR-targeted agents. Careful patient selection through the identification of specific biologic markers, such as gene expression, genomic polymorphism, and posttranslational modifications of EGFR downstream effectors, most likely will contribute to the successful use of these agents.

AB - Background: Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many patients with cancer. Methods: We review the current status of several EGFR-targeted therapies in cancer patients and address the efficacy of theses drugs as monotherapy or in combination with other drugs and/or treatments. Results: Cetuximab is the most widely studied anti-EGFR monoclonal antibody. Other monoclonal antibody agents under investigation are panitumumab, matuzumab, MDX-447, nimutozumab, and mAb806. Extensive research has also evaluated the efficacy of EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib, EKB-569, lapatinib (GW572016), PKI-166, and canertinib (CI-1033). All of these agents have been studied for the treatment of colorectal, lung, breast, pancreatic, renal, head and neck, gynecologic, and prostate cancer. Currently, cetuximab and panitumumab are FDA approved for the treatment of metastatic colorectal cancer. Additionally, cetuximab is approved for head and neck cancer. Erlotinib is FDA approved for advanced/metastatic lung cancer. Erlotinib in combination with gemcitabine is approved for advanced/metastatic pancreatic cancer treatment. Conclusions: EGFR-targeted agents have already shown utility in different scenarios. Researchers are continuously investigating additional cancer types and combined treatment modalities that could also benefit from the use of EGFR-targeted agents. Careful patient selection through the identification of specific biologic markers, such as gene expression, genomic polymorphism, and posttranslational modifications of EGFR downstream effectors, most likely will contribute to the successful use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=34447299692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447299692&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 295

EP - 304

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 3

ER -